Direxion Daily S&P Biotech Bear 3X ETF
LABD
12 hedge funds and large institutions have $35.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
144% more call options, than puts
Call options by funds: $18.6M | Put options by funds: $7.63M
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
9% more funds holding
Funds holding: 11 → 12 (+1)
0.04% more ownership
Funds ownership: 4.46% → 4.51% (+0.04%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
51% less capital invested
Capital invested by funds: $71.9M → $35.5M (-$36.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.18M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.04M |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$222K |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$51.2K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$34.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$19.4M |
| 2 |
VF
Virtu Financial
New York
|
-$3.17M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.05M |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$1.24M |
| 5 |
Jane Street
New York
|
-$1.14M |
LABD Hedge Fund Activity: Q1 2021 in Review
12 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2021, worth a combined $35.5M — down 51% from $71.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LABD positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.18M. The largest seller was Boxer Capital, cutting an estimated $19.4M.
- 12 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2021, up from 11 in Q4 2020.
- Funds reported $35.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2021, down 51% quarter-over-quarter.
- 6 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2021 and 5 closed out, a net change of +1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2021 was Citadel Advisors, an estimated $3.18M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2021 was Boxer Capital, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2021.